Management of HER2-Altered Non-Small Cell Lung Cancer
Oncology Today with Dr Neil Love
00:00
HER3 Antibody Drug Conjugate
The HER3 antibody drug conjugate, Trastuzumab that targets HER3. It has the potential to overcome all types of resistance mechanisms to TKIs. And so you rather than switching it off with the lock and key, you're really just throwing a bomb into the cell and then blows it up with chemotherapy.
Transcript
Play full episode
